( to gettingintestinal adenomas. The eff...)British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer,Health

to getting intestinal adenomas. The effect was dependent on the fiber content of the bran. The dose, which was efficacious in these mice translates into approximately 200g rice bran per day in humans. Some scientists believe that Min mice are a reasonable model of early stages of colorectal cancer in humans. Therefore, we feel that to study the potential colorectal cancer-preventing properties of stabilized rice bran in humans may be a promising idea."

The stabilized rice bran used in the study was NutraCea Stabilized Rice Bran Regular and NutraCea RiSolubles(R), both produced by NutraCea in the U.S. NutraCea's Chief Science Officer, Dr. Rani Madhavapeddi Patel comments, "This recent data validates what we have known about our stabilized rice bran for a long time; that the long-term health benefits have huge potential for the prevention of many of today's critical diseases. Obviously more research is needed, but for people at risk of colon cancer, daily consumption of our stabilized rice bran is a simple and safe way to take a pro-active, preventative approach."

"The fiber content in our stabilized rice bran is about 29%. However, with this study demonstrating that the active ingredient in the rice bran is the fiber, we are even more convinced that our Fiber Complex, which is the insoluble fraction of the rice bran and is comprised of 43% fiber, would produce even more significant results than the stabilized rice bran," Adelman added. "In fact, we don't know what further benefits the high antioxidant and rich phyto-nutrient profile might have added to the fiber's anti-cancer activity. However, we do concur with the researchers that the short chain fatty acids and butyrates formed in the colon from the breakdown of the rice bran are most likely the mechanism that makes the addition of stabilized rice bran to our daily diet a promising treatment for the prevention of colon cancer," said Adelman.

About NutraCea

NutraCea is a world leader in
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
6. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma